After Pfizer's third-quarter results, analysts from Morgan Stanley, RBC, and UBS changed their price targets for the company.

Nov 4, 2026, 4:35 PM ETOpinionRead the original at marketscreener.com

Neutral

Morgan Stanley cut its target to $26, but RBC and UBS raised theirs to $28 and $30. Their split views and unchanged ratings do not show a clear change in Pfizer's business outlook.

PFE · Pfizer

AI read · Neutral

The AI's read

These figures are analyst opinions, not new sales or profit results. Two firms raised targets, but one cut its target. RBC kept Sector Perform and UBS kept Neutral, so the views do not establish a clear change in Pfizer's outlook.

Get alerts for PFE

Follow Pfizer (PFE) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for PFE

Free on the App Store and Google Play, or on the web.